A primary challenge associated with CD47‐targeted therapies is the potential for hematologic toxicity, including anaemia, thrombocytopenia, and leukopenia, due to the widespread expression of CD47 on normal erythrocytes and platelets. The gene discussed is CD47; the disease is Thrombocytopenia.